Check-Cap (NASDAQ:CHEK) Earns Sell Rating from Analysts at StockNews.com

StockNews.com began coverage on shares of Check-Cap (NASDAQ:CHEK) in a research report sent to investors on Thursday. The brokerage issued a sell rating on the medical research company’s stock.

Check-Cap Stock Down 4.9 %

NASDAQ:CHEK opened at $0.68 on Thursday. The company has a market cap of $3.95 million, a P/E ratio of -0.23 and a beta of 0.20. Check-Cap has a twelve month low of $0.56 and a twelve month high of $3.04. The business has a 50 day moving average price of $0.80 and a two-hundred day moving average price of $1.01.

About Check-Cap

Check-Cap Ltd., a clinical stage medical diagnostics company, engages in the development of a capsule-based screening technology that utilizes ultra-low-dose X-rays to scan the inner lining of the colon for precancerous polyps, and other structural abnormalities in Israel. Its C-Scan system consists of C-Scan Cap, an X-ray scanning capsule for detection of suspected polyps; C-Scan Track, a disposable system attached to the patient's back through biocompatible adhesive skin patches; and C-Scan View software, a client/server-based application that enables procedure data download from the C-Scan Track, data analysis, and report generation.